Natco Pharma Performance
- Today's Low
- ₹1,000
- Today's High
- ₹1,202
- 52 Week Low
- ₹789
- 52 Week High
- ₹1,227
- Open Price₹1,161
- Previous Close₹1,176
- Volume3,936,884
- 50 DMA₹1,090.66
- 100 DMA₹1,026.41
- 200 DMA₹982.30
Natco Pharma Chart
Investment Returns
- Over 1 Month -7.1%
- Over 3 Month + 2.77%
- Over 6 Month + 15.81%
- Over 1 Year + 15%
Smart Investing Starts Here Start SIP with Natco Pharma for Steady Growth!
Natco Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 12.8
- PEG Ratio
- -0.5
- Market Cap Cr
- 18,196
- P/B Ratio
- 2.1
- Average True Range
- 49.77
- EPS
- 86.94
- Dividend Yield
- 0.5
- MACD Signal
- 26.72
- RSI
- 33.54
- MFI
- 48.79
Latest Stock News Updates
The total revenue of the Hyderabad - based company too declined 36.5 percent at Rs 816 crore against Rs 1287 crore in the year ago period.
- Business Line
- 2 days 10 hours ago
Pharmaceuticals company Natco Pharma announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Revenue for Q4FY26 stood at Rs 7,391 million, a QoQ increase of 14.18% from Rs 6,473 million but a YoY decline of 39.47% from Rs 12,210 million. For the full year FY26, consolidated revenue was Rs 40,783 million against Rs 44,295 million in FY25. Total Income: Total income for Q4FY26 reached Rs 8,169 million, up 15.81% from Rs 7,054 million in Q3FY26 (QoQ) and down 36.54% from Rs 12,873 million in Q4FY25 (YoY). For the full year FY26, total income was Rs 43,759 million versus Rs 47,840 million in FY25. Profit Before Tax (PBT): Consolidated PBT (before share of profit of associate) for Q4FY26 was Rs 1,441 million, down 10.55% QoQ from Rs 1,611 million and down 71.52% YoY from Rs 5,059 million. Full-year PBT for FY26 was Rs 14,908 million compared to Rs 22,914 million in FY25. Net Profit: Net profit for Q4FY26 was Rs 2,690 million, showing a QoQ growth of 77.79% from Rs 1,513 million and a YoY decline of 33.74% from Rs 4,060 million. For the full year FY26, consolidated net profit was Rs 14,185 million against Rs 18,834 million in FY25. Standalone Financial Highlights: Revenue from Operations: For Q4FY26, revenue was Rs 6,088 million, an increase of 15.13% from Rs 5,288 million in Q3FY26 (QoQ) but a decrease of 47.40% compared to Rs 11,574 million in Q4FY25 (YoY). For the full year FY26, revenue stood at Rs 35,946 million against Rs 40,945 million in FY25. Total Income: Total income for Q4FY26 was Rs 6,817 million, representing a QoQ growth of 16.71% from Rs 5,841 million and a YoY decline of 44.10% from Rs 12,195 million. Full year total income was Rs 38,757 million compared to Rs 44,158 million in the previous year. Profit Before Tax (PBT): For Q4FY26, PBT was Rs 1,100 million, a decrease of 12.14% QoQ from Rs 1,252 million and a decrease of 78.88% YoY from Rs 5,208 million. Full-year PBT for FY26 was Rs 13,641 million versus Rs 22,260 million in FY25. Net Profit: The company reported a net profit of Rs 2,096 million for Q4FY26, up 96.07% over Rs 1,069 million in Q3FY26 (QoQ) but down 51.04% compared to Rs 4,281 million in Q4FY25 (YoY). For the full year FY26, net profit was Rs 12,815 million compared to Rs 18,504 million in FY25. Business Highlights Segmental Revenue Split (Consolidated): Active Pharmaceutical Ingredients (API): Revenue for Q4FY26 was Rs 63.9 crore, and full-year FY26 revenue was Rs 234.7 crore. Domestic Formulations: Revenue for Q4FY26 was Rs 108.7 crore, and full-year FY26 revenue was Rs 440.9 crore. Formulations export (Including profit share and subsidiaries): Revenue for Q4FY26 was Rs 539.6 crore, and full-year FY26 revenue was Rs 3,234.5 crore. Crop Health Sciences (CHS): Revenue for Q4FY26 was Rs 22.6 crore, and full-year FY26 revenue was Rs 138.2 crore. Other operating and non-operating income: Revenue for Q4FY26 stood at Rs 82.1 crore, and for FY26 was Rs 327.5 crore. South African Acquisition: NATCO completed the acquisition of a 35.75% equity stake in Adcock Ingram Holdings Limited, South Africa, on November 11, 2025, for a consideration of ZAR 3,873 million (approximately Rs 19,912 million). For FY26, the Group recognized a share of profit of Rs 466 million (net of tax) from this associate. Agro Chemical Business Demerger: The Board of Directors approved a Scheme of Arrangement for the demerger of the company's Agro Chemical business undertaking into NATCO Crop Health Sciences Limited, a newly incorporated wholly owned subsidiary. Tax Regime Election: The company elected to move to the new tax regime under Section 115BAA of the Income-tax Act, 1961, effective from FY26-27. This re-measurement of deferred tax assets resulted in a one-time benefit of Rs 1,150 million (Rs 115 crore) recognized during the quarter and year ended March 31, 2026. Dividends: The Board has approved a total dividend of Rs 5 per equity share on equity shares of face value Rs 2 each for the financial year ended March 31, 2026, including interim dividends. Result PDF
- Trendlyne
- 2 days 11 hours ago
As per the scheme, theshareholders would receive shares in the resulting company in a 1:1 ratio.
- Business Line
- 2 months 1 week ago
Natco Pharma Financials
Natco Pharma Technicals
EMA & SMA
- Bearish Moving Average 12
- Bullish Moving Average 4
- 20 Day
- ₹1,141.13
- 50 Day
- ₹1,090.66
- 100 Day
- ₹1,026.41
- 200 Day
- ₹982.30
Resistance and Support
- R3 1,347.10
- R2 1,274.50
- R1 1,145.20
- S1 943.30
- S2 870.70
- S3 741.40
Natco Pharma Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-29 | Audited Results | |
| 2026-03-24 | Scheme of Arrangement | Inter alia, to consider among other things, the Scheme of Arrangement for the demerger of Agrochemicals Division on a going concern basis into its WoS i.e., Natco Crop Health Sciences Limited. per share(100%)Interim Dividend |
| 2026-02-12 | Quarterly Results & Interim Dividend | |
| 2025-11-14 | Quarterly Results & Interim Dividend | |
| 2025-08-12 | Quarterly Results & Interim Dividend |
About Natco Pharma
Natco Pharma Ltd. is leading pharmaceutical company in India, specializing in production of generic medicines, bulk drugs, & specialty pharmaceuticals. Founded in 1981, Natco has established itself as key player in global pharmaceutical industry, with strong focus on oncology, cardiology, & gastroenterology segments. company operates state of the art manufacturing facilities that comply with global regulatory standards, ensuring production of high quality medicines. Natco Pharma is known for its innovation, particularly in development of affordable generic versions of high cost drugs, which has made it preferred partner for healthcare providers worldwide.
NATCO Pharma Limited (NATCO) is pharmaceutical firm that focuses on research & development & is vertically integrated. Its core competencies include creating, producing, & selling complicated pharmaceuticals for specific therapeutic areas. NATCO is now present in three business categories of contract manufacturing business, active pharmaceutical ingredients (APIs), & final dosage formulations (FDF).
- NSE Symbol
- NATCOPHARM
- BSE Symbol
- 524816
- Chairman & Managing Director
- Mr. V C Nannapaneni
- ISIN
- INE987B01026
Similar Stocks to Natco Pharma
Popular Stocks
Natco Pharma FAQs
Natco Pharma share price is ₹1,015 As on 01 June, 2026 | 03:35
The Market Cap of Natco Pharma is ₹18195.8 Cr As on 01 June, 2026 | 03:35
The P/E ratio of Natco Pharma is 12.8 As on 01 June, 2026 | 03:35
The PB ratio of Natco Pharma is 2.1 As on 01 June, 2026 | 03:35
Evaluate company's performance in pharmaceutical industry & its product pipeline before investing
Key metrics include revenue growth, product approvals, & profit margins.
Open Demat account with 5 Paisa Capital & post doing KYC & active account search for Natco Pharma share, you can then put order as you prefer.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.